

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	"Ask CAS" for self-help around the clock
NEWS	3 May 12	EXTEND option available in structure searching
NEWS	4 May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS	5 May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAplus
NEWS	6 May 27	CAplus super roles and document types searchable in REGISTRY
NEWS	7 Jun 28	Additional enzyme-catalyzed reactions added to CASREACT
NEWS	8 Jun 28	ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS	9 Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS	10 Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS	11 AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS	12 AUG 02	CAplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS	13 AUG 02	STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS	14 AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS EXPRESS	JULY 30	CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS INTER		General Internet Information
NEWS LOGIN		Welcome Banner and News Items
NEWS PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:04:37 ON 03 AUG 2004

=> file medline, uspatful, dgene, embase, wpids, fsta,		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION

FULL ESTIMATED COST

0.42

0.42

FILE 'MEDLINE' ENTERED AT 12:05:52 ON 03 AUG 2004

FILE 'USPATFULL' ENTERED AT 12:05:52 ON 03 AUG 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 12:05:52 ON 03 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 12:05:52 ON 03 AUG 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 12:05:52 ON 03 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 12:05:52 ON 03 AUG 2004
COPYRIGHT (C) 2004 International Food Information Service

=> s annexin

L1 12293 ANNEXIN

=> s MDR or multidrug resistance or multi-drug resistance
5 FILES SEARCHED...

L2 40790 MDR OR MULTIDRUG RESISTANCE OR MULTI-DRUG RESISTANCE

=> s l2 and inhibition

L3 6951 L2 AND INHIBITION

=> s l3 and Annexin I

L4 10 L3 AND ANNEXIN I

=> d l4 ti abs ibib tot

L4 ANSWER 1 OF 10 USPATFULL on STN

TI Lectin compositions and methods for modulating an immune response to an antigen

AB The present invention provides a fusion polypeptide which can bind to a cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand for a cell surface polypeptide, as well as a vector comprising a nucleic acid encoding for such a fusion polypeptide, and a host cell comprising such nucleic acid. The present invention also provides a composition comprising an antigen bearing target and such a fusion polypeptide, as well as a composition comprising a virus or a cell and such a fusion polypeptide. The present invention further relates to a method of modulating an immune response in an animal using such compositions.

ACCESSION NUMBER: 2004:185003 USPATFULL

TITLE: Lectin compositions and methods for modulating an immune response to an antigen

INVENTOR(S): Segal, Andrew H., Boston, MA, UNITED STATES
Young, Elihu, Sharon, MA, UNITED STATES

PATENT ASSIGNEE(S): Genitrix, LLC (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004142889	A1	20040722
APPLICATION INFO.:	US 2003-666898	A1	20030919 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-404823P	20020820 (60)

US 2003-487407P 20030715 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111
HUNTINGTON AVENUE, BOSTON, MA, 02199
NUMBER OF CLAIMS: 69
EXEMPLARY CLAIM: 1
LINE COUNT: 7754

L4 ANSWER 2 OF 10 USPATFULL on STN

TI Lectin compositions and methods for modulating an immune response to an antigen

AB The present invention provides a fusion polypeptide which can bind to a cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand for a cell surface polypeptide, as well as a vector comprising a nucleic acid encoding for such a fusion polypeptide, and a host cell comprising such nucleic acid. The present invention also provides a composition comprising an antigen bearing target and such a fusion polypeptide, as well as a composition comprising a virus or a cell and such a fusion polypeptide. The present invention further relates to a method of modulating an immune response in an animal using such compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:165307 USPATFULL
TITLE: Lectin compositions and methods for modulating an immune response to an antigen
INVENTOR(S): Segal, Andrew H., Boston, MA, UNITED STATES
Young, Elihu, Sharon, MA, UNITED STATES
PATENT ASSIGNEE(S): Genitrix, LLC (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004126793	A1	20040701
APPLICATION INFO.:	US 2003-666885	A1	20030919 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-404823P	20020820 (60)
	US 2003-487407P	20030715 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111
HUNTINGTON AVENUE, BOSTON, MA, 02199
NUMBER OF CLAIMS: 147
EXEMPLARY CLAIM: 1
LINE COUNT: 28979

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 10 USPATFULL on STN

TI Lectin compositions and methods for modulating an immune response to an antigen

AB The present invention provides a fusion polypeptide which can bind to a cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand for a cell surface polypeptide, as well as a vector comprising a nucleic acid encoding for such a fusion polypeptide, and a host cell comprising such nucleic acid. The present invention also provides a composition comprising an antigen bearing target and such a fusion polypeptide, as well as a composition comprising a virus or a cell and such a fusion polypeptide. The present invention further relates to a method of modulating an immune response in an animal using such compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:164872 USPATFULL
TITLE: Lectin compositions and methods for modulating an
immune response to an antigen
INVENTOR(S): Segal, Andrew H., Boston, MA, UNITED STATES
Young, Elihu, Sharon, MA, UNITED STATES
PATENT ASSIGNEE(S): Genitrix, LLC (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004126357	A1	20040701
APPLICATION INFO.:	US 2003-666886	A1	20030919 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-404823P	20020820 (60)
	US 2003-487407P	20030715 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
LINE COUNT:	39007	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 10 USPATFULL on STN
TI Lectin compositions and methods for modulating an immune response to an
antigen
AB The present invention provides a fusion polypeptide which can bind to a
cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand
for a cell surface polypeptide, as well as a vector comprising a nucleic
acid encoding for such a fusion polypeptide, and a host cell comprising
such nucleic acid. The present invention also provides a composition
comprising an antigen bearing target and such a fusion polypeptide, as
well as a composition comprising a virus or a cell and such a fusion
polypeptide. The present invention further relates to a method of
modulating an immune response in an animal using such compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:159413 USPATFULL
TITLE: Lectin compositions and methods for modulating an
immune response to an antigen
INVENTOR(S): Segal, Andrew H., Boston, MA, UNITED STATES
Young, Elihu, Sharon, MA, UNITED STATES
PATENT ASSIGNEE(S): Genitrix, LLC (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004122217	A1	20040624
APPLICATION INFO.:	US 2003-666871	A1	20030919 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-404823P	20020820 (60)
	US 2003-487407P	20030715 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199	
NUMBER OF CLAIMS:	68	

EXEMPLARY CLAIM: 1
LINE COUNT: 7880
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 10 USPATFULL on STN

TI Lectin compositions and methods for modulating an immune response to an antigen

AB The present invention provides a fusion polypeptide which can bind to a cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand for a cell surface polypeptide, as well as a vector comprising a nucleic acid encoding for such a fusion polypeptide, and a host cell comprising such nucleic acid. The present invention also provides a composition comprising an antigen bearing target and such a fusion polypeptide, as well as a composition comprising a virus or a cell and such a fusion polypeptide. The present invention further relates to a method of modulating an immune response in an animal using such compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:120097 USPATFULL
TITLE: Lectin compositions and methods for modulating an immune response to an antigen
INVENTOR(S): Segal, Andrew H., Boston, MA, UNITED STATES
Young, Elihu, Sharon, MA, UNITED STATES
PATENT ASSIGNEE(S): Genitrix, LLC (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004091503	A1	20040513
APPLICATION INFO.:	US 2003-645000	A1	20030820 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-404823P	20020820 (60)
	US 2003-487407P	20030715 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199	
NUMBER OF CLAIMS:	78	
EXEMPLARY CLAIM:	1	
LINE COUNT:	7933	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 10 USPATFULL on STN

TI Lectin compositions and methods for modulating an immune response to an antigen

AB The present invention relates to a fusion polypeptide comprising at least about 10 contiguous amino acid residues of an influenza virus hemagglutinin and at least about 5 contiguous amino acids of a naturally occurring GM-CSF molecule.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:51725 USPATFULL
TITLE: Lectin compositions and methods for modulating an immune response to an antigen
INVENTOR(S): Segal, Andrew, Boston, MA, UNITED STATES
Young, Eli, Sharon, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004039156	A1	20040226
APPLICATION INFO.:	US 2002-224661	A1	20020820 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		

LEGAL REPRESENTATIVE: PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111
HUNTINGTON AVENUE, BOSTON, MA, 02199
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 7091
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 10 USPATFULL on STN
TI Selections of genes and methods of using the same for diagnosis and for
targeting the therapy of select cancers
AB A method of diagnosing a disease that includes obtaining experimental
data on gene selections. The gene selection functions to characterize a
cancer when the expression of that gene selection is compared to the
identical selection from a noncancerous cell or a different type of
cancer cell. The invention also includes a method of targeting at least
one product of a gene that includes administration of a therapeutic
agent. The invention also includes the use of a gene selection for
diagnosing a cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:12636 USPATFULL
TITLE: Selections of genes and methods of using the same for
diagnosis and for targeting the therapy of select
cancers
INVENTOR(S): Khan, Javed, Derwood, MD, UNITED STATES
Ringner, Markus, Lund, SWEDEN
Peterson, Carsten, Lund, SWEDEN
Meltzer, Paul, Rockville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009154	A1	20040115
APPLICATION INFO.:	US 2002-159563	A1	20020531 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-133937, filed on 25 Apr 2002, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MERCHANT & GOULD PC, 3200 IDS CENTER, 80 SOUTH EIGHTH STREET, MINNEAPOLIS, MN, 55402-0903		
NUMBER OF CLAIMS:	101		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	9 Drawing Page(s)		
LINE COUNT:	3943		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 10 USPATFULL on STN
TI Expression profile of prostate cancer
AB The present invention relates to compositions and methods for cancer
diagnostics, including but not limited to, cancer markers. In
particular, the present invention provides gene expression profiles
associated with prostate cancers. Genes identified as cancer markers
using the methods of the present invention find use in the diagnosis and
characterization of prostate cancer. In addition, the genes provide
targets for cancer drug screens and therapeutic applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:250950 USPATFULL
TITLE: Expression profile of prostate cancer
INVENTOR(S): Chinnaiyan, Arul M., Plymouth, MI, UNITED STATES
Rubin, Mark A., Ann Arbor, MI, UNITED STATES
Sreekumar, Arun, Ann Arbor, MI, UNITED STATES
PATENT ASSIGNEE(S): The Regents of the University of Michigan, Ann Arbor,
MI (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003175736	A1	20030918
APPLICATION INFO.:	US 2002-210120	A1	20020801 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-309581P	20010802 (60)
	US 2001-334468P	20011115 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Tanya A. Arenson, MELDEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA, 94105	
NUMBER OF CLAIMS:	101	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	129 Drawing Page(s)	
LINE COUNT:	11938	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L4 ANSWER 9 OF 10 USPATFULL on STN

TI Protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction

AB The invention relates to protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction. Using overlapping hexapeptides that encode for the entire amino acid sequences of the linker domains of human P-glycoprotein gene 1 and 3 (HP-gp1 and HP-gp3), a direct and specific binding between P-gp1 and 3 linker domains and intracellular proteins was demonstrated. Three different stretches (.sup.617EKGIYFKLVMT.sup.627, .sup.658SRSSLIRKRSTRRSVRGSQA.sup.677 and .sup.694PVSFWRIMKLNLT.sup.706 for P-gp1 and .sup.618LMKKEGVYFKLVNM.sup.631, .sup.64KAATRMAMPNGWKSRLFRHSTQKNLKNS.sup.674 and .sup.695PVSFVKLVKLKNT.sup.677 for P-gp3) in linker domains bound to proteins with apparent molecular masses of .about.80 kDa, 57 kDa and 30 kDa. The binding of the 57 kDa protein was further characterized. Purification and partial N-terminal amino acid sequencing of the 57 kDa protein showed that it encodes the N-terminal amino acids of alpha and beta-tubulins. The method of the present invention was further validated with Annexin. The present invention thus demonstrates a novel concept whereby the interactions between two proteins are mediated by strings of few amino acids with high and repulsive binding energies, enabling the identification of high-affinity binding sites between any interacting proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:258778 USPATFULL

TITLE: Protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction

INVENTOR(S): Georges, Elias, Laval, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002142348	A1	20021003
APPLICATION INFO.:	US 2001-10310	A1	20011113 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2000-CA587, filed on 12 May 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-134259P	19990514 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HALE AND DORR, LLP, 60 STATE STREET, BOSTON, MA, 02109	

NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Page(s)
LINE COUNT: 2044
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 10 USPATFULL on STN
TI Taxol resistance associated gene
AB A gene overexpressed in taxol-resistant cancer cell lines is disclosed.
The gene is designated Taxol Resistance Associated Gene-3 ("TRAG-3"). At
least two alternatively spliced forms of TRAG-3 exist. TRAG-3
polypeptides, TRAG-3 antibodies, and TRAG-3-related screening methods
useful in drug discovery are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:64018 USPATFULL
TITLE: Taxol resistance associated gene
INVENTOR(S): Seiden, Michael V., Wayland, MA, United States
Duan, Zhenfeng, Cambridge, MA, United States
Feller, Aynn, Somerville, MA, United States
PATENT ASSIGNEE(S): The General Hospital Corporation, Boston, MA, United
States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6362321	B1	20020326
APPLICATION INFO.:	US 1999-277303		19990326 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-79771P	19980327 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Caputa, Anthony C.	
ASSISTANT EXAMINER:	Harris, Alana M.	
LEGAL REPRESENTATIVE:	Fish & Richardson, P.C.	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 4 Drawing Page(s)	
LINE COUNT:	1036	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:04:37 ON 03 AUG 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 12:05:52
ON 03 AUG 2004

L1 12293 S ANNEXIN
L2 40790 S MDR OR MULTIDRUG RESISTANCE OR MULTI-DRUG RESISTANCE
L3 6951 S L2 AND INHIBITION
L4 10 S L3 AND ANNEXIN I

=> s l1 with MDR

MISSING OPERATOR L1 WITH

The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s annexin with MDR

L5 1 ANNEXIN WITH MDR

=> d l5 ti abs ibib tot

*Applicant
priority date*

L5 ANSWER 1 OF 1 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
TI Modulating or assessing multidrug resistance related to annexin proteins.
AN 1999-337419 [28] WPIDS
AB WO 9921980 A UPAB: 19990719

NOVELTY - Isolated nucleic acid (I) encoding an annexin family member (II), i.e. a member of the MDR (multidrug resistance) gene family, for assessing or modulating MDR in a cell, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a method for detecting and assessing **annexin**-based **MDR** by treating test sample with an oligonucleotide (ON) containing 10-50 nucleotides (nt) that hybridize specifically to RNA and/or DNA encoding an annexin, ON being complementary to a sequence of at least 10 consecutive nt from the sequences for annexins I to IX, and detecting any hybrids formed;

(2) kits for this method;

(3) recombinant vector for modulating, inhibiting and/or increasing **annexin**-based **MDR** in a cell, containing (I) linked to a promoter;

(4) cells containing this vector;

(5) a method for identifying compounds that affect **annexin**-based **MDR** by incubating with test compound in presence or absence of a drug and assessing any effect of the test compound on resistance to the drug;

(6) a method of reducing **annexin**-based **MDR** by administering a nucleic acid, (dominant negative) mutant of annexin, antibody to annexin, peptide or small molecule;

(7) pharmaceutical composition for reducing MDR comprising **annexin**-based **MDR**-affecting compound and a carrier; and

(8) methods for diagnosing presence of, or predisposition to, **annexin**-based **MDR** in a patient or pathogen.

ACTIVITY - Antitumor; antifungal.

MECHANISM OF ACTION - None given.

USE - Antisense sequences from (I), or any other agent that inhibits (II), are used to prevent MDR in animals, particularly in conjunction with cancer treatment. Detecting levels of (II), or related RNA, is used to detect cancer (or pathogens) with MDR, or susceptibility. (II) can also be used as a target for identifying therapeutic agents, e.g. antifungal agents, and increasing (II) expression in plants may be used to develop specific resistance.

Dwg.0/9

ACCESSION NUMBER: 1999-337419 [28] WPIDS
DOC. NO. NON-CPI: N1999-252873
DOC. NO. CPI: C1999-099183
TITLE: Modulating or assessing multidrug resistance related to annexin proteins.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): GEORGES, E; WANG, Y
PATENT ASSIGNEE(S): (UYMC-N) UNIV MCGILL; (GEOR-I) GEORGES E; (WANG-I) WANG Y
COUNTRY COUNT: 83
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9921980	A1	19990506	(199928)*	EN	62
RW:	AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL				
	OA PT SD SE SZ UG ZW				
W:	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE				
	GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG				
	MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG				
	US UZ VN YU ZW				
AU 9896174	A	19990517	(199939)		
CA 2219299	A1	19990424	(199940)	EN	
EP 1025225	A1	20000809	(200039)	EN	

R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9921980	A1	WO 1998-CA992	19981026
AU 9896174	A	AU 1998-96174	19981026
CA 2219299	A1	CA 1997-2219299	19971024
EP 1025225	A1	EP 1998-949842	19981026
		WO 1998-CA992	19981026

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9896174	A Based on	WO 9921980
EP 1025225	A1 Based on	WO 9921980

PRIORITY APPLN. INFO: CA 1997-2219299 19971024

=> s l1 and drug resistance
L6 434 L1 AND DRUG RESISTANCE

=> s l6 and inhibit
=> s l6 and inhibit?
L7 351 L6 AND INHIBIT?

=> s l7 and (Annexin I)?
MISSING OPERATOR I)?
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l7 and (annexin I)
L8 12 L7 AND (ANNEXIN I)

=> d l8 ti abs ibib tot

L8 ANSWER 1 OF 12 MEDLINE on STN
TI Dexamethasone-induced cytotoxic activity and **drug**
resistance effects in androgen-independent prostate tumor PC-3
cells are mediated by lipocortin 1.
AB We have examined the effects that dexamethasone (DEX), alone or in
combination with doxorubicin (DOX), cisplatin (CDDP), or etoposide
(VP-16), exerts on the growth of the androgen-independent prostate cancer
PC-3 cells. DEX exhibited only a limited cytotoxicity (growth
inhibition of about 28% or 20% after 24 or 72 h of exposure,
respectively, in the range of DEX 10-100 nM) and did not induce apoptosis
in the cells. This cytotoxicity of DEX was mimicked by an active peptide
(peptide Ac2-26) drawn from the human lipocortin 1 N-terminus region and
abrogated by an antibody to human lipocortin 1. Two **inhibitors**
of arachidonic acid metabolism, tenidap and indomethacin, also caused
cytotoxicity. The cytotoxic effects of DEX in combination with DOX, CDDP,
or VP-16 were antagonistic when the steroid was administered 3 h before or
simultaneously with the drugs. Other schedule-dependency experiments
further clarified that, at least in the case of the combination with DOX,
it is the steroid that desensitizes the cells to the drug. When peptide
Ac2-26, tenidap, or indomethacin were tested in combination with DOX,
antagonism was also observed. DEX treatment neither modified the ability
of the cells to accumulate DOX nor changed their weak expression of
P-glycoprotein. PC-3 cells also produce IL-6, which autocrinally
stimulates their growth, and whose gene expression may be reduced by
glucocorticoids. In the present experiments DEX only slightly decreased

the production and secretion of IL-6 by the cells. The present findings suggest that the slight cytotoxic activity and the **drug resistance** effects of DEX on PC-3 cells are mediated by induction of lipocortin 1 and **inhibition** of arachidonic acid metabolism, with no relationship to downregulation of IL-6 levels. These findings indicate also that the combination of DEX with conventional chemotherapeutic agents may result in antagonistic antitumor effects.

ACCESSION NUMBER: 1999018867 MEDLINE
DOCUMENT NUMBER: PubMed ID: 9802059
TITLE: Dexamethasone-induced cytotoxic activity and **drug resistance** effects in androgen-independent prostate tumor PC-3 cells are mediated by lipocortin 1.
AUTHOR: Carollo M; Parente L; D'Alessandro N
CORPORATE SOURCE: Institute of Pharmacology, Faculty of Medicine, University of Palermo, Italy.
SOURCE: Oncology research, (1998) 10 (5) 245-54.
Journal code: 9208097. ISSN: 0965-0407.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199901
ENTRY DATE: Entered STN: 19990115
Last Updated on STN: 19990115
Entered Medline: 19990104

L8 ANSWER 2 OF 12 MEDLINE on STN

TI Possible mechanisms of glucocorticoid--unresponsive pyrexia. Defect in lipocortin 1?.

AB Glucocorticoids have a strong anti-inflammatory action, and are indispensable in the treatment of inflammatory diseases. We had a patient with the Weber-Christian disease having an intractable high fever that did not respond to even a high-dose glucocorticoid therapy, but was responsive to a nonsteroidal antiinflammatory drug. To elucidate possible mechanisms of the glucocorticoid-unresponsive fever, we have investigated the in vitro production of two eicosanoids, prostaglandin (PG)E2 and leukotriene (LT)B4, from the peripheral blood polymorphonuclear leukocytes after stimulation by ionophore A23187. The patient's leukocytes produced much larger amount of PGE2, but the same amount of LTB4, as did those of two control groups. More interestingly, the production of eicosanoids was **inhibited** by dexamethasone less in the patients than in the controls. Indomethacin suppressed the production of PGE2 both in the patients and in the controls. These results might be relevant in the glucocorticoid-unresponsive pyrexia.

ACCESSION NUMBER: 97089287 MEDLINE
DOCUMENT NUMBER: PubMed ID: 8935195
TITLE: Possible mechanisms of glucocorticoid--unresponsive pyrexia. Defect in lipocortin 1?.
AUTHOR: Akama H; Tanaka H; Kawai S
CORPORATE SOURCE: Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
SOURCE: Materia medica Polona. Polish journal of medicine and pharmacy, (1995 Apr-Jun) 27 (2) 75-8.
Journal code: 0236526. ISSN: 0025-5246.
PUB. COUNTRY: Poland
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199612
ENTRY DATE: Entered STN: 19970128
Last Updated on STN: 19970128
Entered Medline: 19961223

L8 ANSWER 3 OF 12 MEDLINE on STN

TI High-level expression of human lipocortin I in the fission yeast
Schizosaccharomyces pombe using a novel expression vector.

AB We have developed a novel expression system that allows the fission yeast,
Schizosaccharomyces pombe, to be used for the efficient overproduction of
heterologous proteins. As an example of the utility of this system, human
lipocortin I was expressed to 50 percent of soluble protein, and 150 mg of
highly purified material was obtained from 10 grams of wet cell paste.
Expression of lipocortin I was driven by the human cytomegalovirus (hCMV)
promoter in a vector that also contains a neomycin resistance gene (neo)
under the control of the SV40 early promoter, permitting selection for
increasing copy-number with increasing concentrations of the antibiotic
G418. The purified protein was equivalent to its native counterpart with
respect to antigenicity and biochemical properties such as phospholipase
A2 **inhibition**, actin binding and N-terminal acetylation. We
have also used this system to produce comparable amounts of other proteins
including rat arginase, rat NDP-kinase and human interleukin-6.

ACCESSION NUMBER: 94226791 MEDLINE
DOCUMENT NUMBER: PubMed ID: 7764687
TITLE: High-level expression of human lipocortin I in the fission
yeast Schizosaccharomyces pombe using a novel expression
vector.

AUTHOR: Giga-Hama Y; Tohda H; Okada H; Owada M K; Okayama H;
Kumagai H

CORPORATE SOURCE: Research Center, Asahi Glass Co. Ltd, Kanagawa, Japan.
SOURCE: Bio/technology (Nature Publishing Company), (1994 Apr) 12
(4) 400-4.
Journal code: 8309273. ISSN: 0733-222X.

PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Biotechnology
ENTRY MONTH: 199406
ENTRY DATE: Entered STN: 19950809
Last Updated on STN: 19950809
Entered Medline: 19940609

L8 ANSWER 4 OF 12 USPATFULL on STN

TI Molecular toxicology modeling

AB The present invention is based on the elucidation of the global changes
in gene expression and the identification of toxicity markers in tissues
or cells exposed to a known renal toxin. The genes may be used as
toxicity markers in drug screening and toxicity assays. The invention
includes a database of genes characterized by toxin-induced differential
expression that is designed for use with microarrays and other
solid-phase probes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:94708 USPATFULL
TITLE: Molecular toxicology modeling
INVENTOR(S): Mendrick, Donna, Gaithersburg, MD, UNITED STATES
Porter, Mark, Gaithersburg, MD, UNITED STATES
Johnson, Kory, Gaithersburg, MD, UNITED STATES
Higgs, Brandon, Gaithersburg, MD, UNITED STATES
Castle, Arthur, Gaithersburg, MD, UNITED STATES
Elashoff, Michael, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004072160	A1	20040415
APPLICATION INFO.:	US 2002-152319	A1	20020522 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-292335P	20010522 (60)

US 2001-297523P	20010613 (60)
US 2001-298925P	20010619 (60)
US 2001-303810P	20010710 (60)
US 2001-303807P	20010710 (60)
US 2001-303808P	20010710 (60)
US 2001-315047P	20010828 (60)
US 2001-324928P	20010927 (60)
US 2001-330867P	20011101 (60)
US 2001-330462P	20011022 (60)
US 2001-331805P	20011121 (60)
US 2001-336144P	20011206 (60)
US 2001-340873P	20011219 (60)
US 2002-357843P	20020221 (60)
US 2002-357842P	20020221 (60)
US 2002-357844P	20020221 (60)
US 2002-364134P	20020315 (60)
US 2002-370206P	20020408 (60)
US 2002-370247P	20020408 (60)
US 2002-370144P	20020408 (60)
US 2002-371679P	20020412 (60)
US 2002-372794P	20020417 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE
NW, WASHINGTON, DC, 20004
NUMBER OF CLAIMS: 59
EXEMPLARY CLAIM: 1
LINE COUNT: 27909
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 12 USPATFULL on STN
TI Expression profile of prostate cancer
AB The present invention relates to compositions and methods for cancer
diagnostics, including but not limited to, cancer markers. In
particular, the present invention provides gene expression profiles
associated with prostate cancers. Genes identified as cancer markers
using the methods of the present invention find use in the diagnosis and
characterization of prostate cancer. In addition, the genes provide
targets for cancer drug screens and therapeutic applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:250950 USPATFULL
TITLE: Expression profile of prostate cancer
INVENTOR(S): Chinnaiyan, Arul M., Plymouth, MI, UNITED STATES
Rubin, Mark A., Ann Arbor, MI, UNITED STATES
Sreekumar, Arun, Ann Arbor, MI, UNITED STATES
PATENT ASSIGNEE(S): The Regents of the University of Michigan, Ann Arbor,
MI (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003175736	A1	20030918
APPLICATION INFO.:	US 2002-210120	A1	20020801 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-309581P	20010802 (60)
	US 2001-334468P	20011115 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Tanya A. Arenson, MELDEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA, 94105	
NUMBER OF CLAIMS:	101	
EXEMPLARY CLAIM:	1	

NUMBER OF DRAWINGS: 129 Drawing Page(s)
LINE COUNT: 11938
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 12 USPATFULL on STN
TI Libraries of expressible gene sequences
AB The invention described herein comprises libraries of expressible gene sequences. Such gene sequences are contained on plasmid vectors designed to endow the expressed proteins with a number of useful features such as affinity purification tags, epitope tags, and the like. The expression vectors containing such gene sequences can be used to transfect cells for the production of recombinant proteins. A further aspect of the invention comprises methods of identifying binding partners for the products of such expressible gene sequences.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:194491 USPATFULL
TITLE: Libraries of expressible gene sequences
INVENTOR(S): Fernandez, Joseph Manuel, Carlsbad, CA, UNITED STATES
Heyman, John Alastair, Cardiff-by-the-Sea, CA, UNITED STATES
Hoeffler, James Paul, Carlsbad, CA, UNITED STATES
PATENT ASSIGNEE(S): INVITROGEN CORPORATION (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003134302	A1	20030717
APPLICATION INFO.:	US 2002-210985	A1	20020801 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-3021, filed on 14 Nov 2001, PENDING Continuation of Ser. No. US 1999-285386, filed on 2 Apr 1999, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-96981P	19980818 (60)
	US 1998-80626P	19980403 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Lisa A. Haile, J.D., Ph.D., GRAY CARY WARE & FREIDENRICH LLP, Suite 1100, 4365 Executive Drive, San Diego, CA, 92121-2133	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	9810	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 12 USPATFULL on STN
TI Libraries of expressible gene sequences
AB The invention described herein comprises libraries of expressible gene sequences. Such gene sequences are contained on plasmid vectors designed to endow the expressed proteins with a number of useful features such as affinity purification tags, epitope tags, and the like. The expression vectors containing such gene sequences can be used to transfect cells for the production of recombinant proteins. A further aspect of the invention comprises methods of identifying binding partners for the products of such expressible gene sequences.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:106252 USPATFULL
TITLE: Libraries of expressible gene sequences
INVENTOR(S): Fernandez, Joseph Manuel, Carlsbad, CA, UNITED STATES
Heyman, John Alastair, Cardiff-by-the-Sea, CA, UNITED STATES

PATENT ASSIGNEE(S): Hoeffler, James Paul, Carlsbad, CA, UNITED STATES
INVITROGEN CORPORATION (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003073163	A1	20030417
APPLICATION INFO.:	US 2001-3021	A1	20011114 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-285386, filed on 2 Apr 1999, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-96981P	19980818 (60)
	US 1998-80626P	19980403 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Lisa A. Haile, J.D., Ph.D., GRAY CARY WARE & FREIDENRICH LLP, Suite 1100, 4365 Executive Drive, San Diego, CA, 92121-2133	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	9813	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L8 ANSWER 8 OF 12 USPATFULL on STN

TI Early stage multipotential stem cells in colonies of bone marrow stromal cells

AB Marrow stromal cells (MSCs) are adult stem cells from bone marrow that can differentiate into multiple non-hematopoietic cell lineages. Colonies of human MSCs were shown to contain both small, rapidly self-renewing stem cells (RS cells) and large, more mature cells (mMSCs). Samples enriched for RS cells had a greater potential for multipotential differentiation than samples enriched for mMSCs. Also, RS cells have a series of surface epitopes and expressed proteins that can be used to differentiate RS cells from mMSCs. The results suggest that it will be important to distinguish the two major sub-populations of MSCs in defining their biology and their potentials for cell and gene therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:301221 USPATFULL

TITLE: Early stage multipotential stem cells in colonies of bone marrow stromal cells

INVENTOR(S): Prockop, Darwin J., New Orleans, LA, UNITED STATES
Colter, David C., Philadelphia, PA, UNITED STATES
Sekiya, Ichiro, New Orleans, LA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002168765	A1	20021114
APPLICATION INFO.:	US 2001-816182	A1	20010323 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MORGAN, LEWIS & BOCKIUS LLP, 1701 Market Street, Philadelphia, PA, 19103		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Page(s)		
LINE COUNT:	570		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L8 ANSWER 9 OF 12 USPATFULL on STN

TI Protein-protein interactions and methods for identifying interacting

AB proteins and the amino acid sequence at the site of interaction
The invention relates to protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction. Using overlapping hexapeptides that encode for the entire amino acid sequences of the linker domains of human P-glycoprotein gene 1 and 3 (HP-gp1 and HP-gp3), a direct and specific binding between P-gp1 and 3 linker domains and intracellular proteins was demonstrated. Three different stretches (.sup.617EKGIFYFKLVMT.sup.627, .sup.658SRSSLIRKRSTRRSVRGSQA.sup.677 and .sup.694PVSFWRIMKLNLT.sup.706 for P-gp1 and .sup.618LMKKEGVYFKLVNM.sup.631, .sup.64KAATRMAMPNGWKSRLFRHSTQKNLKNS.sup.674 and .sup.695PVSFVLKVLKLNKT.sup.677 for P-gp3) in linker domains bound to proteins with apparent molecular masses of .about.80 kDa, 57 kDa and 30 kDa. The binding of the 57 kDa protein was further characterized. Purification and partial N-terminal amino acid sequencing of the 57 kDa protein showed that it encodes the N-terminal amino acids of alpha and beta-tubulins. The method of the present invention was further validated with **Annexin**. The present invention thus demonstrates a novel concept whereby the interactions between two proteins are mediated by strings of few amino acids with high and repulsive binding energies, enabling the identification of high-affinity binding sites between any interacting proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:258778 USPATFULL
TITLE: Protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction
INVENTOR(S): Georges, Elias, Laval, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002142348	A1	20021003
APPLICATION INFO.:	US 2001-10310	A1	20011113 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2000-CA587, filed on 12 May 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-134259P	19990514 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HALE AND DORR, LLP, 60 STATE STREET, BOSTON, MA, 02109	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	16 Drawing Page(s)	
LINE COUNT:	2044	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 12 USPATFULL on STN

TI Nucleic acids, proteins and antibodies

AB This invention relates to newly identified tissue specific cancer associated polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cancer antigens," and to the complete gene sequences associated therewith and to the expression products thereof, as well as the use of such tissue specific cancer antigens for detection, prevention and treatment of tissue specific disorders, particularly the presense of cancer. This invention relates to the cancer antigens as well as vectors, host cells, antibodies directed to cancer antigens and recombinant and synthetic methods for producing the same. Also provided are diagnostic methods for diagnosing and treating, preventing and/or prognosing tissue specific disorders, including cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying

agonists and antagonists of cancer antigens of the invention. The present invention further relates to methods and/or compositions for **inhibiting** the production and/or function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:99407 USPATFULL
TITLE: Nucleic acids, proteins and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002052308	A1	20020502
APPLICATION INFO.:	US 2001-925301	A1	20010810 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2000-US5882, filed on 8 Mar 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-124270P	19990312 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
LINE COUNT:	30577	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 11 OF 12 USPATFULL on STN
TI Taxol resistance associated gene
AB A gene overexpressed in taxol-resistant cancer cell lines is disclosed. The gene is designated Taxol Resistance Associated Gene-3 ("TRAG-3"). At least two alternatively spliced forms of TRAG-3 exist. TRAG-3 polypeptides, TRAG-3 antibodies, and TRAG-3-related screening methods useful in drug discovery are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:64018 USPATFULL
TITLE: Taxol resistance associated gene
INVENTOR(S): Seiden, Michael V., Wayland, MA, United States
Duan, Zhenfeng, Cambridge, MA, United States
Feller, Aynn, Somerville, MA, United States
PATENT ASSIGNEE(S): The General Hospital Corporation, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6362321	B1	20020326
APPLICATION INFO.:	US 1999-277303		19990326 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-79771P	19980327 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Caputa, Anthony C.	
ASSISTANT EXAMINER:	Harris, Alana M.	
LEGAL REPRESENTATIVE:	Fish & Richardson, P.C.	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 4 Drawing Page(s)	
LINE COUNT:	1036	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 12 OF 12 USPATFULL on STN
TI Human single nucleotide polymorphisms
AB The invention provides nucleic acid segments of the human genome, particularly nucleic acid segments from genes including polymorphic sites. Allele-specific primers and probes hybridizing to regions flanking or containing these sites are also provided. The nucleic acids, primers and probes are used in applications such as phenotype correlations, forensics, paternity testing, medicine and genetic analysis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:55155 USPATFULL
TITLE: Human single nucleotide polymorphisms
INVENTOR(S): Cargill, Michele, Gaithersburg, MD, UNITED STATES
Ireland, James S., Gaithersburg, MD, UNITED STATES
Lander, Eric S., Cambridge, MA, UNITED STATES
PATENT ASSIGNEE(S): Whitehead Institute for Biomedical Research, Cambridge, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002032319	A1	20020314
APPLICATION INFO.:	US 2001-801274	A1	20010307 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-187510P	20000307 (60)
	US 2000-206129P	20000522 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HAMILTON BROOK SMITH AND REYNOLDS, P.C., TWO MILITIA DR, LEXINGTON, MA, 02421-4799	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
LINE COUNT:	8981	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:04:37 ON 03 AUG 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 12:05:52 ON 03 AUG 2004

L1 12293 S ANNEXIN
L2 40790 S MDR OR MULTIDRUG RESISTANCE OR MULTI-DRUG RESISTANCE
L3 6951 S L2 AND INHIBITION
L4 10 S L3 AND ANNEXIN I
L5 1 S ANNEXIN WITH MDR
L6 434 S L1 AND DRUG RESISTANCE
L7 351 S L6 AND INHIBIT?
L8 12 S L7 AND (ANNEXIN I)

=> file medline

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	69.66	70.08

FILE 'MEDLINE' ENTERED AT 12:17:25 ON 03 AUG 2004

FILE LAST UPDATED: 1 AUG 2004 (20040801/UP). FILE COVERS 1951 TO DATE.

On February 29, 2004, the 2004 MeSH terms were loaded. See HELP RLOAD for details. OLDMEDLINE now back to 1951.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2004 vocabulary. See <http://www.nlm.nih.gov/mesh/> and http://www.nlm.nih.gov/pubs/techbull/nd03/nd03_mesh.html for a description of changes.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s P-40+NT/CT
'P-40' NOT IN RELATIONSHIP FILE
RELATIONSHIP CODE 'NT' IGNORED
L9          0 P-40+NT/CT (1 TERM)
```

```
=> e "P-40"
E1          1      OZZT/BI
E2          2307533 P/BI
E3          0 --> P-40/BI
E4          2984   P0/BI
E5          4      P00/BI
E6          1      P000/BI
E7          1      P00004/BI
E8          1      P00037/BI
E9          3      P0004/BI
E10         5      P0006/BI
E11         8      P001/BI
E12         1      P00126/BI
```

```
=> e P-40/CT
E#  FREQUENCY  AT  TERM
--  -
E1      0      1  P-286/CT
E2      0      2  P-286 (CONTRAST MEDIA)/CT
E3      0      --> P-40/CT
E4      0      1  P-450/CT
E5      0      2  P-450 4A, CYTOCHROME/CT
E6      0      2  P-450 CYP2D6, CYTOCHROME/CT
E7      0      2  P-450 CYP4A, CYTOCHROME/CT
E8      0      2  P-450 IVA, CYTOCHROME/CT
E9      0      2  P-450 OXIDASE, CYTOCHROME/CT
E10     0      1  P-450-CAM/CT
E11     0      1  P-450-DEPENDENT/CT
E12     0      2  P-450-DEPENDENT O-DEALKYLASE, CYTOCHROME/CT
```

```
=> s "p-40"
      2307533 "P"
      397211 "40"
L10    1433 "P-40"
      ("P" (W) "40")
```

```
=> s l10 and l1
L11          4 L10 AND L1
```

```
=> d l11 ti abs ibib tot
```

```
L11  ANSWER 1 OF 4      MEDLINE on STN
```

```
TI  Annexin-I expression modulates drug resistance in tumor cells.
```

```
AB  The use of anti-cancer chemotherapy often leads to the rise of
multidrug-resistant (MDR) tumors. We have previously reported the
overexpression of a 40kDa protein (P-40) in several
MDR tumor cell lines. In this report we describe the cloning of a 1.4kb
cDNA with an open reading frame of 344 amino acids that encodes the
```

P-40 protein. Analysis of the **P-40** amino acid sequence showed it is identical to the human **annexin I** (Anx-I) protein. The identity of the isolated **P-40** cDNA as Anx-I was confirmed by the specific binding of IPM96 mAb to a 40kDa protein following the in vitro expression of **P-40** full-length cDNA. Northern blot analysis of total RNA from drug-sensitive and -resistant cells revealed an increase in **P-40** (or Anx-I) mRNA in drug-resistant cells relative to drug-sensitive cells. Transfection of Anx-I cDNA into drug-sensitive MCF-7 cells was carried out without further drug selection and showed 2- to 5-fold increase in resistance of transfected cells to adriamycin, melphalan, and etoposide. Conversely, transfection of reverse Anx-I cDNA into SKOV-3 cells decreased the expression of Anx-I without affecting the expression of other members of the **annexin** family and showed a 3- to 8-fold increase in sensitivity to these drugs. Of interest was the correlation between the presence of Anx-I and MDR in MDA-MB-231 cells when compared to MCF-7 cells. MDA-MB-231 cells show 3- to 20-fold increase in resistance to adriamycin, melphalan, and etoposide in the absence of detectable levels of P-glycoprotein (P-gp1), the multidrug resistance protein (MRP1) or the breast cancer resistance protein (BCRP). Taken together, these results provide the first direct evidence for the role of Anx-I in MDR of tumor cells.

ACCESSION NUMBER: 2004033900 MEDLINE
DOCUMENT NUMBER: PubMed ID: 14733945
TITLE: **Annexin**-I expression modulates drug resistance in tumor cells.
AUTHOR: Wang Ying; Serfass Lucile; Roy Marie Odile; Wong Judy; Bonneau Anne Marie; Georges Elias
CORPORATE SOURCE: Institute of Parasitology, McGill University, Macdonald Campus, Ste-Anne de Bellevue, Que., Canada.
SOURCE: Biochemical and biophysical research communications, (2004 Feb 6) 314 (2) 565-70.
Journal code: 0372516. ISSN: 0006-291X.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200403
ENTRY DATE: Entered STN: 20040122
Last Updated on STN: 20040306
Entered Medline: 20040305

L11 ANSWER 2 OF 4 MEDLINE on STN
TI GTP-induced membrane binding and ion channel activity of **annexin** VI: is **annexin** VI a GTP biosensor?.
AB **Annexin** VI (AnxVI) formed ion channels in planar lipid bilayers that were induced by the addition of millimolar guanosine 5'-triphosphate (GTP) at pH 7.4 and that were not accompanied by a penetration of the protein into the membrane hydrophobic region. GTP-influenced interactions of AnxVI with Ca²⁺/liposomes produced small structural alterations as revealed by circular dichroism and infrared spectroscopies. Guanosine 5'-3-O-(thio)-triphosphate (GTPgammaS) binding to AnxVI, promoted by the photorelease of GTPgammaS from GTPgammaS[1-(4,5-dimethoxy-2-nitrophenyl)-ethyl] (caged-GTPgammaS), affected three to four amino acid residues of AnxVI in the presence of Ca²⁺/liposomes, while about eight or nine amino acid residues were altered in their absence. This suggested that the nucleotide-binding site overlapped the lipid-binding domain of AnxVI. The binding of the fluorescent GTP analog, 2'-(or 3')-O-(2,4,6-trinitrophenyl)guanosine 5'-triphosphate (TNP-GTP) to AnxVI was optimal in the presence of Ca²⁺/liposomes, with a dissociation constant (K(d)) of 1 microM and stoichiometry of 1. TNP-GTP promoted fluorescence resonance energy transfer from tryptophan residues to the nucleotide. Ion conductance and fluorescence measurements of the C- and N-terminal fragments of AnxVI indicated distinct GTP-binding properties, suggesting

that the existence of the GTP-induced ion channel activity of AnxVI is associated with the flexibility of the two halves of the protein. Such structural flexibility could contribute to a molecular mechanism of AnxVI acting as a GTP biosensor.

ACCESSION NUMBER: 2002246408 MEDLINE
DOCUMENT NUMBER: PubMed ID: 11964259
TITLE: GTP-induced membrane binding and ion channel activity of **annexin** VI: is **annexin** VI a GTP biosensor?.
AUTHOR: Kirilenko Aneta; Golczak Marcin; Pikula Slawomir; Buchet Rene; Bandorowicz-Pikula Joanna
CORPORATE SOURCE: Department of Cellular Biochemistry, Nencki Institute of Experimental Biology, 02-093 Warsaw, Poland.
SOURCE: Biophysical journal, (2002 May) 82 (5) 2737-45.
Journal code: 0370626. ISSN: 0006-3495.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200209
ENTRY DATE: Entered STN: 20020503
Last Updated on STN: 20020925
Entered Medline: 20020924

L11 ANSWER 3 OF 4 MEDLINE on STN

TI Annexins V and XII insert into bilayers at mildly acidic pH and form ion channels.

AB The functional hallmark of annexins is the ability to bind to the surface of phospholipid membranes in a reversible, Ca(2+)-dependent manner. We now report that human **annexin** V and hydra **annexin** XII reversibly bound to phospholipid vesicles in the absence of Ca(2+) at low pH; half-maximal vesicle association occurred at pH 5.3 and 5.8, respectively. The following biochemical data support the hypothesis that these annexins insert into bilayers at mildly acidic pH. First, a photoactivatable reagent (3-trifluoromethyl)-3-(m-[(125)I]iodophenyl)diazirine) which selectively labels proteins exposed to the hydrophobic domain of bilayers reacted with these annexins at pH 5.0 and below but not at neutral pH. Second, in a Triton X-114 partitioning assay, annexins V and XII act as integral membrane proteins at low pH and as hydrophilic proteins at neutral pH; in the presence of phospholipids half-maximal partitioning into detergent occurred at pH approximately 5.0. Finally, **annexin** V or XII formed single channels in phospholipid bilayers at low pH but not at neutral pH. A model is discussed in which the concentrations of H(+) and Ca(2+) regulate the reversible conversion of three forms of annexins-soluble, peripheral membrane, and transmembrane.

ACCESSION NUMBER: 2000181674 MEDLINE
DOCUMENT NUMBER: PubMed ID: 10715122
TITLE: Annexins V and XII insert into bilayers at mildly acidic pH and form ion channels.
AUTHOR: Isas J M; Cartailier J P; Sokolov Y; Patel D R; Langen R; Luecke H; Hall J E; Haigler H T
CORPORATE SOURCE: Department of Physiology and Biophysics, University of California, Irvine, California 92697, USA.
CONTRACT NUMBER: GM55651 (NIGMS)
GM56445 (NIGMS)
GM57998 (NIGMS)
SOURCE: Biochemistry, (2000 Mar 21) 39 (11) 3015-22.
Journal code: 0370623. ISSN: 0006-2960.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200004

ENTRY DATE: Entered STN: 20000427
Last Updated on STN: 20000427
Entered Medline: 20000414

L11 ANSWER 4 OF 4 MEDLINE on STN

TI Anomalous changes in forward scatter of lymphocytes with loosely packed membranes.

AB BACKGROUND: Forward scatter (FSC) is generally associated with cell size and has been suggested as a way to differentiate apoptotic from viable cells. Among spleen cells cultured for 48 h, a population of cells (population B) was found to have decreased forward and increased side scatter relative to freshly purified cells (population A). Interestingly, population B was not present early in analysis; this report explores the change in FSC of population B. METHODS: Using a Coulter (Hialeah, FL) Epics Elite ESP flow cytometer, changes in forward scatter and lipid packing of spleen cells were measured. RESULTS: Over time, the FSC of unfixed cells in population B increased from that of the debris field, to reach a stable value by 30 sec (population A's FSC remained constant). When fixed, populations A and B exhibited constant FSC. Population B cells displayed altered lipid packing as reported by MC540, and the FSC changes were mimicked by Nonidet P-40 treatment of freshly purified spleen cells. CONCLUSIONS: Data emphasize the importance of delaying measurements on unfixed cells until FSC readings have stabilized, and suggest that flow cytometry may be a useful tool in studying lipid packing.

Copyright 1999 Wiley-Liss, Inc.

ACCESSION NUMBER: 1999451075 MEDLINE

DOCUMENT NUMBER: PubMed ID: 10520198

TITLE: Anomalous changes in forward scatter of lymphocytes with loosely packed membranes.

AUTHOR: Scherer J M; Stillwell W; Jensi L J

CORPORATE SOURCE: Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana..
jscherer@iupui.edu

CONTRACT NUMBER: R01CA57212 (NCI)

SOURCE: Cytometry : journal of the Society for Analytical Cytology, (1999 Nov 1) 37 (3) 184-90.

Journal code: 8102328. ISSN: 0196-4763.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199911

ENTRY DATE: Entered STN: 20000111

Last Updated on STN: 20000111

Entered Medline: 19991119

=> e wang, Y/au

E1 4 WANG ZUOYUAN/AU

E2 2 WANG ZUYI/AU

E3 0 --> WANG, Y/AU

E4 1 WANG1 Y/AU

E5 1 WANGA D B/AU

E6 1 WANGA I/AU

E7 2 WANGA J/AU

E8 1 WANGA K C/AU

E9 1 WANGA K K/AU

E10 1 WANGA MIKE A/AU

E11 1 WANGA O/AU

E12 1 WANGA X J/AU

=> e georges, E/au

E1 3 GEORGES W/AU

E2	3	GEORGES Y/AU
E3	0 -->	GEORGES, E/AU
E4	1	GEORGESC M/AU
E5	1	GEORGESCAUD D/AU
E6	23	GEORGESCAULD D/AU
E7	1	GEORGESCAULT D/AU
E8	8	GEORGESCO A/AU
E9	1	GEORGESCO B/AU
E10	14	GEORGESCO C/AU
E11	2	GEORGESCO D/AU
E12	1	GEORGESCO E/AU

=> file scisearch

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

5.44

75.52

FILE 'SCISEARCH' ENTERED AT 12:24:40 ON 03 AUG 2004

COPYRIGHT 2004 THOMSON ISI

FILE COVERS 1974 TO 29 Jul 2004 (20040729/ED)

=> e Georges, E/au

E1	2	GEORGES Y/AU
E2	1	GEORGES YATES E/AU
E3	0 -->	GEORGES, E/AU
E4	5	GEORGESC C/AU
E5	4	GEORGESC D/AU
E6	2	GEORGESC II/AU
E7	2	GEORGESC M/AU
E8	2	GEORGESC S/AU
E9	1	GEORGESC V/AU
E10	1	GEORGESCAUD D/AU
E11	29	GEORGESCAULD D/AU
E12	1	GEORGESCAULT D/AU

=> e wang, y/au

E1	336	WANG Z Z/AU
E2	2	WANG ZHU Y R/AU
E3	0 -->	WANG, Y/AU
E4	1	WANGA M A/AU
E5	1	WANGA O/AU
E6	1	WANGA T/AU
E7	1	WANGA X S/AU
E8	1	WANGA Z Z/AU
E9	9	WANGAARD C/AU
E10	2	WANGAARD C H/AU
E11	2	WANGAARD D B/AU
E12	4	WANGAARD F F/AU

=> file medline, uspatful, dgene, embase, wpids, fsta, wpids, japio, biobusiness, jicst, biosis

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

4.12

79.64

FILE 'MEDLINE' ENTERED AT 12:25:47 ON 03 AUG 2004

FILE 'USPATFULL' ENTERED AT 12:25:47 ON 03 AUG 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 12:25:47 ON 03 AUG 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 12:25:47 ON 03 AUG 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 12:25:47 ON 03 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 12:25:47 ON 03 AUG 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'JAPIO' ENTERED AT 12:25:47 ON 03 AUG 2004
COPYRIGHT (C) 2004 Japanese Patent Office (JPO)- JAPIO

FILE 'BIOBUSINESS' ENTERED AT 12:25:47 ON 03 AUG 2004
COPYRIGHT (C) 2004 Biological Abstracts, Inc. (BIOSIS)

FILE 'JICST-EPLUS' ENTERED AT 12:25:47 ON 03 AUG 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'BIOSIS' ENTERED AT 12:25:47 ON 03 AUG 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

=> s multi-drug resistance or MDR or multidrug resistance
L12 55745 MULTI-DRUG RESISTANCE OR MDR OR MULTIDRUG RESISTANCE

=> s l12 and inhibit?
L13 19635 L12 AND INHIBIT?

=> s annexin I
L14 1405 ANNEXIN I

=> s l14 an dl13
MISSING OPERATOR L14 AN
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l14 and l13
L15 17 L14 AND L13

=> d l15 ti abs ibib tot

L15 ANSWER 1 OF 17 USPATFULL on STN
TI Lectin compositions and methods for modulating an immune response to an
antigen
AB The present invention provides a fusion polypeptide which can bind to a
cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand
for a cell surface polypeptide, as well as a vector comprising a nucleic
acid encoding for such a fusion polypeptide, and a host cell comprising
such nucleic acid. The present invention also provides a composition
comprising an antigen bearing target and such a fusion polypeptide, as
well as a composition comprising a virus or a cell and such a fusion
polypeptide. The present invention further relates to a method of
modulating an immune response in an animal using such compositions.

ACCESSION NUMBER: 2004:185003 USPATFULL
TITLE: Lectin compositions and methods for modulating an
immune response to an antigen
INVENTOR(S): Segal, Andrew H., Boston, MA, UNITED STATES
Young, Elihu, Sharon, MA, UNITED STATES
PATENT ASSIGNEE(S): Genitrix,LLC (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004142889	A1	20040722	
APPLICATION INFO.:	US 2003-666898	A1	20030919	(10)

RELATED APPLN. INFO.: Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-404823P	20020820 (60)
	US 2003-487407P	20030715 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199	
NUMBER OF CLAIMS:	69	
EXEMPLARY CLAIM:	1	
LINE COUNT:	7754	

L15 ANSWER 2 OF 17 USPATFULL on STN

TI Lectin compositions and methods for modulating an immune response to an antigen

AB The present invention provides a fusion polypeptide which can bind to a cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand for a cell surface polypeptide, as well as a vector comprising a nucleic acid encoding for such a fusion polypeptide, and a host cell comprising such nucleic acid. The present invention also provides a composition comprising an antigen bearing target and such a fusion polypeptide, as well as a composition comprising a virus or a cell and such a fusion polypeptide. The present invention further relates to a method of modulating an immune response in an animal using such compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:165307 USPATFULL

TITLE: Lectin compositions and methods for modulating an immune response to an antigen

INVENTOR(S): Segal, Andrew H., Boston, MA, UNITED STATES
Young, Elihu, Sharon, MA, UNITED STATES

PATENT ASSIGNEE(S): Genitrix, LLC (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004126793	A1	20040701
APPLICATION INFO.:	US 2003-666885	A1	20030919 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-404823P	20020820 (60)
	US 2003-487407P	20030715 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199	
NUMBER OF CLAIMS:	147	
EXEMPLARY CLAIM:	1	
LINE COUNT:	28979	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 3 OF 17 USPATFULL on STN

TI Lectin compositions and methods for modulating an immune response to an antigen

AB The present invention provides a fusion polypeptide which can bind to a cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand for a cell surface polypeptide, as well as a vector comprising a nucleic acid encoding for such a fusion polypeptide, and a host cell comprising such nucleic acid. The present invention also provides a composition

comprising an antigen bearing target and such a fusion polypeptide, as well as a composition comprising a virus or a cell and such a fusion polypeptide. The present invention further relates to a method of modulating an immune response in an animal using such compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:164872 USPATFULL
TITLE: Lectin compositions and methods for modulating an immune response to an antigen
INVENTOR(S): Segal, Andrew H., Boston, MA, UNITED STATES
Young, Elihu, Sharon, MA, UNITED STATES
PATENT ASSIGNEE(S): Genitrix, LLC (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004126357	A1	20040701
APPLICATION INFO.:	US 2003-666886	A1	20030919 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-404823P	20020820 (60)
	US 2003-487407P	20030715 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
LINE COUNT:	39007	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 4 OF 17 USPATFULL on STN

TI Lectin compositions and methods for modulating an immune response to an antigen

AB The present invention provides a fusion polypeptide which can bind to a cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand for a cell surface polypeptide, as well as a vector comprising a nucleic acid encoding for such a fusion polypeptide, and a host cell comprising such nucleic acid. The present invention also provides a composition comprising an antigen bearing target and such a fusion polypeptide, as well as a composition comprising a virus or a cell and such a fusion polypeptide. The present invention further relates to a method of modulating an immune response in an animal using such compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:159413 USPATFULL
TITLE: Lectin compositions and methods for modulating an immune response to an antigen
INVENTOR(S): Segal, Andrew H., Boston, MA, UNITED STATES
Young, Elihu, Sharon, MA, UNITED STATES
PATENT ASSIGNEE(S): Genitrix, LLC (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004122217	A1	20040624
APPLICATION INFO.:	US 2003-666871	A1	20030919 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-404823P	20020820 (60)

US 2003-487407P 20030715 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111
HUNTINGTON AVENUE, BOSTON, MA, 02199
NUMBER OF CLAIMS: 68
EXEMPLARY CLAIM: 1
LINE COUNT: 7880
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 5 OF 17 USPATFULL on STN

TI Targets for therapeutic intervention identified in the mitochondrial
proteome
AB Mitochondrial targets for drug screening assays and for therapeutic
intervention in the treatment of diseases associated with altered
mitochondrial function are provided. Complete amino acid sequences [SEQ
ID NOS:1-3025] of polypeptides that comprise the human heart
mitochondrial proteome are provided, using fractionated proteins derived
from highly purified mitochondrial preparations, to identify previously
unrecognized mitochondrial molecular components.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:133338 USPATFULL
TITLE: Targets for therapeutic intervention identified in the
mitochondrial proteome
INVENTOR(S): Ghosh, Soumitra S., San Diego, CA, UNITED STATES
Fahy, Eoin D., San Diego, CA, UNITED STATES
Zhang, Bing, Spring, TX, UNITED STATES
Gibson, Bradford W., Berkeley, CA, UNITED STATES
Taylor, Steven W., San Diego, CA, UNITED STATES
Glenn, Gary M., Encinitas, CA, UNITED STATES
Warnock, Dale E., San Diego, CA, UNITED STATES
Gaucher, Sara P., Castro Valley, CA, UNITED STATES
PATENT ASSIGNEE(S): MitoKor Inc., San Diego, CA, UNITED STATES, 92121 (U.S.
corporation)
The Buck Institute for Age Research, Novato, CA, UNITED
STATES, 94948-0638 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004101874	A1	20040527
APPLICATION INFO.:	US 2003-408765	A1	20030404 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-412418P	20020920 (60)
	US 2002-389987P	20020617 (60)
	US 2002-372843P	20020412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH
AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 5998
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 6 OF 17 USPATFULL on STN

TI Lectin compositions and methods for modulating an immune response to an
antigen
AB The present invention provides a fusion polypeptide which can bind to a
cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand
for a cell surface polypeptide, as well as a vector comprising a nucleic

acid encoding for such a fusion polypeptide, and a host cell comprising such nucleic acid. The present invention also provides a composition comprising an antigen bearing target and such a fusion polypeptide, as well as a composition comprising a virus or a cell and such a fusion polypeptide. The present invention further relates to a method of modulating an immune response in an animal using such compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:120097 USPATFULL
TITLE: Lectin compositions and methods for modulating an
immune response to an antigen
INVENTOR(S): Segal, Andrew H., Boston, MA, UNITED STATES
Young, Elihu, Sharon, MA, UNITED STATES
PATENT ASSIGNEE(S): Genitrix, LLC (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004091503	A1	20040513
APPLICATION INFO.:	US 2003-645000	A1	20030820 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-404823P	20020820 (60)
	US 2003-487407P	20030715 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199	
NUMBER OF CLAIMS:	78	
EXEMPLARY CLAIM:	1	
LINE COUNT:	7933	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 7 OF 17 USPATFULL on STN

TI Molecular toxicology modeling
AB The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known renal toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:94708 USPATFULL
TITLE: Molecular toxicology modeling
INVENTOR(S): Mendrick, Donna, Gaithersburg, MD, UNITED STATES
Porter, Mark, Gaithersburg, MD, UNITED STATES
Johnson, Kory, Gaithersburg, MD, UNITED STATES
Higgs, Brandon, Gaithersburg, MD, UNITED STATES
Castle, Arthur, Gaithersburg, MD, UNITED STATES
Elashoff, Michael, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004072160	A1	20040415
APPLICATION INFO.:	US 2002-152319	A1	20020522 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-292335P	20010522 (60)
	US 2001-297523P	20010613 (60)
	US 2001-298925P	20010619 (60)
	US 2001-303810P	20010710 (60)

US 2001-303807P	20010710 (60)
US 2001-303808P	20010710 (60)
US 2001-315047P	20010828 (60)
US 2001-324928P	20010927 (60)
US 2001-330867P	20011101 (60)
US 2001-330462P	20011022 (60)
US 2001-331805P	20011121 (60)
US 2001-336144P	20011206 (60)
US 2001-340873P	20011219 (60)
US 2002-357843P	20020221 (60)
US 2002-357842P	20020221 (60)
US 2002-357844P	20020221 (60)
US 2002-364134P	20020315 (60)
US 2002-370206P	20020408 (60)
US 2002-370247P	20020408 (60)
US 2002-370144P	20020408 (60)
US 2002-371679P	20020412 (60)
US 2002-372794P	20020417 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE
NW, WASHINGTON, DC, 20004
NUMBER OF CLAIMS: 59
EXEMPLARY CLAIM: 1
LINE COUNT: 27909
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 8 OF 17 USPATFULL on STN

TI Lectin compositions and methods for modulating an immune response to an antigen
AB The present invention relates to a fusion polypeptide comprising at least about 10 contiguous amino acid residues of an influenza virus hemagglutinin and at least about 5 contiguous amino acids of a naturally occurring GM-CSF molecule.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:51725 USPATFULL
TITLE: Lectin compositions and methods for modulating an immune response to an antigen
INVENTOR(S): Segal, Andrew, Boston, MA, UNITED STATES
Young, Eli, Sharon, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004039156	A1	20040226
APPLICATION INFO.:	US 2002-224661	A1	20020820 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
LINE COUNT:	7091		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 9 OF 17 USPATFULL on STN

TI Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers
AB A method of diagnosing a disease that includes obtaining experimental data on gene selections. The gene selection functions to characterize a cancer when the expression of that gene selection is compared to the identical selection from a noncancerous cell or a different type of cancer cell. The invention also includes a method of targeting at least one product of a gene that includes administration of a therapeutic

agent. The invention also includes the use of a gene selection for diagnosing a cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:12636 USPATFULL
TITLE: Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers
INVENTOR(S): Khan, Javed, Derwood, MD, UNITED STATES
Ringner, Markus, Lund, SWEDEN
Peterson, Carsten, Lund, SWEDEN
Meltzer, Paul, Rockville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009154	A1	20040115
APPLICATION INFO.:	US 2002-159563	A1	20020531 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-133937, filed on 25 Apr 2002, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MERCHANT & GOULD PC, 3200 IDS CENTER, 80 SOUTH EIGHTH STREET, MINNEAPOLIS, MN, 55402-0903		
NUMBER OF CLAIMS:	101		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	9 Drawing Page(s)		
LINE COUNT:	3943		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 10 OF 17 USPATFULL on STN

TI Expression profile of prostate cancer
AB The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with prostate cancers. Genes identified as cancer markers using the methods of the present invention find use in the diagnosis and characterization of prostate cancer. In addition, the genes provide targets for cancer drug screens and therapeutic applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:250950 USPATFULL
TITLE: Expression profile of prostate cancer
INVENTOR(S): Chinnaiyan, Arul M., Plymouth, MI, UNITED STATES
Rubin, Mark A., Ann Arbor, MI, UNITED STATES
Sreekumar, Arun, Ann Arbor, MI, UNITED STATES
PATENT ASSIGNEE(S): The Regents of the University of Michigan, Ann Arbor, MI (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003175736	A1	20030918
APPLICATION INFO.:	US 2002-210120	A1	20020801 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-309581P	20010802 (60)
	US 2001-334468P	20011115 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Tanya A. Arenson, MELDEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA, 94105	
NUMBER OF CLAIMS:	101	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	129 Drawing Page(s)	

LINE COUNT: 11938
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 11 OF 17 USPATFULL on STN

TI Libraries of expressible gene sequences

AB The invention described herein comprises libraries of expressible gene sequences. Such gene sequences are contained on plasmid vectors designed to endow the expressed proteins with a number of useful features such as affinity purification tags, epitope tags, and the like. The expression vectors containing such gene sequences can be used to transfect cells for the production of recombinant proteins. A further aspect of the invention comprises methods of identifying binding partners for the products of such expressible gene sequences.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:194491 USPATFULL

TITLE: Libraries of expressible gene sequences

INVENTOR(S): Fernandez, Joseph Manuel, Carlsbad, CA, UNITED STATES
Heyman, John Alastair, Cardiff-by-the-Sea, CA, UNITED STATES

Hoeffler, James Paul, Carlsbad, CA, UNITED STATES
PATENT ASSIGNEE(S): INVITROGEN CORPORATION (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003134302	A1	20030717
APPLICATION INFO.:	US 2002-210985	A1	20020801 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-3021, filed on 14 Nov 2001, PENDING Continuation of Ser. No. US 1999-285386, filed on 2 Apr 1999, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-96981P	19980818 (60)
	US 1998-80626P	19980403 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Lisa A. Haile, J.D., Ph.D., GRAY CARY WARE & FREIDENRICH LLP, Suite 1100, 4365 Executive Drive, San Diego, CA, 92121-2133	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	9810	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 12 OF 17 USPATFULL on STN

TI Libraries of expressible gene sequences

AB The invention described herein comprises libraries of expressible gene sequences. Such gene sequences are contained on plasmid vectors designed to endow the expressed proteins with a number of useful features such as affinity purification tags, epitope tags, and the like. The expression vectors containing such gene sequences can be used to transfect cells for the production of recombinant proteins. A further aspect of the invention comprises methods of identifying binding partners for the products of such expressible gene sequences.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:106252 USPATFULL

TITLE: Libraries of expressible gene sequences

INVENTOR(S): Fernandez, Joseph Manuel, Carlsbad, CA, UNITED STATES
Heyman, John Alastair, Cardiff-by-the-Sea, CA, UNITED STATES

Hoeffler, James Paul, Carlsbad, CA, UNITED STATES

PATENT ASSIGNEE(S): INVITROGEN CORPORATION (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003073163	A1	20030417
APPLICATION INFO.:	US 2001-3021	A1	20011114 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-285386, filed on 2 Apr 1999, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-96981P	19980818 (60)
	US 1998-80626P	19980403 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Lisa A. Haile, J.D., Ph.D., GRAY CARY WARE & FREIDENRICH LLP, Suite 1100, 4365 Executive Drive, San Diego, CA, 92121-2133	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	9813	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L15 ANSWER 13 OF 17 USPATFULL on STN

TI Early stage multipotential stem cells in colonies of bone marrow stromal cells

AB Marrow stromal cells (MSCs) are adult stem cells from bone marrow that can differentiate into multiple non-hematopoietic cell lineages. Colonies of human MSCs were shown to contain both small, rapidly self-renewing stem cells (RS cells) and large, more mature cells (mMSCs). Samples enriched for RS cells had a greater potential for multipotential differentiation than samples enriched for mMSCs. Also, RS cells have a series of surface epitopes and expressed proteins that can be used to differentiate RS cells from mMSCs. The results suggest that it will be important to distinguish the two major sub-populations of MSCs in defining their biology and their potentials for cell and gene therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:301221 USPATFULL
TITLE: Early stage multipotential stem cells in colonies of bone marrow stromal cells
INVENTOR(S): Prockop, Darwin J., New Orleans, LA, UNITED STATES
Colter, David C., Philadelphia, PA, UNITED STATES
Sekiya, Ichiro, New Orleans, LA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002168765	A1	20021114
APPLICATION INFO.:	US 2001-816182	A1	20010323 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MORGAN, LEWIS & BOCKIUS LLP, 1701 Market Street, Philadelphia, PA, 19103		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Page(s)		
LINE COUNT:	570		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L15 ANSWER 14 OF 17 USPATFULL on STN

TI Protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction

AB The invention relates to protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction. Using overlapping hexapeptides that encode for the entire amino acid sequences of the linker domains of human P-glycoprotein gene 1 and 3 (HP-gp1 and HP-gp3), a direct and specific binding between P-gp1 and 3 linker domains and intracellular proteins was demonstrated. Three different stretches (.sup.617EKGIYFKLVMTM.sup.627, .sup.658SRSSLIRKRSTRRSVRGSQA.sup.677 and .sup.694PVSFWRIMKLNLT.sup.706 for P-gp1 and .sup.618LMKKEGVYFKLVNM.sup.631, .sup.64KAATRMAMPNGWKSRLFRHSTQKNLKNS.sup.674 and .sup.695PVSFLKVLKLNKT.sup.677 for P-gp3) in linker domains bound to proteins with apparent molecular masses of .about.80 kDa, 57 kDa and 30 kDa. The binding of the 57 kDa protein was further characterized. Purification and partial N-terminal amino acid sequencing of the 57 kDa protein showed that it encodes the N-terminal amino acids of alpha and beta-tubulins. The method of the present invention was further validated with Annexin. The present invention thus demonstrates a novel concept whereby the interactions between two proteins are mediated by strings of few amino acids with high and repulsive binding energies, enabling the identification of high-affinity binding sites between any interacting proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:258778 USPATFULL
TITLE: Protein-protein interactions and methods for
identifying interacting proteins and the amino acid
sequence at the site of interaction
INVENTOR(S): Georges, Elias, Laval, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002142348	A1	20021003
APPLICATION INFO.:	US 2001-10310	A1	20011113 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2000-CA587, filed on 12 May 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-134259P	19990514 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HALE AND DORR, LLP, 60 STATE STREET, BOSTON, MA, 02109	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	16 Drawing Page(s)	
LINE COUNT:	2044	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 15 OF 17 USPATFULL on STN

TI Taxol resistance associated gene

AB A gene overexpressed in taxol-resistant cancer cell lines is disclosed. The gene is designated Taxol Resistance Associated Gene-3 ("TRAG-3"). At least two alternatively spliced forms of TRAG-3 exist. TRAG-3 polypeptides, TRAG-3 antibodies, and TRAG-3-related screening methods useful in drug discovery are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:64018 USPATFULL
TITLE: Taxol resistance associated gene
INVENTOR(S): Seiden, Michael V., Wayland, MA, United States
Duan, Zhenfeng, Cambridge, MA, United States
Feller, Aynn, Somerville, MA, United States
PATENT ASSIGNEE(S): The General Hospital Corporation, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6362321	B1	20020326
APPLICATION INFO.:	US 1999-277303		19990326 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-79771P	19980327 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Caputa, Anthony C.	
ASSISTANT EXAMINER:	Harris, Alana M.	
LEGAL REPRESENTATIVE:	Fish & Richardson, P.C.	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 4 Drawing Page(s)	
LINE COUNT:	1036	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 16 OF 17 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
 TI Population of cells useful in cell and gene therapy comprise two classes of bone marrow stem cells, small and rapidly self-renewing stem cells, and large more mature marrow stromal cells .

AN 2003-328406 [31] WPIDS

AB US2002168765 A UPAB: 20030516

NOVELTY - A population (I) of small and rapidly self-renewing stem (RS) cells or a population (II) of large, more mature marrow stromal cells (mMSC), is new. The cells within (I) express one or more polypeptides such as vascular endothelial growth factor (VEGF) receptor-2 (FLK-1), TRK (an NGF receptor), transferrin receptor, and annexin II (lipocortin 2).

DETAILED DESCRIPTION - A population (I) of small and rapidly self-renewing stem (RS) cells or a population (II) of large, more mature marrow stromal cells (mMSC) express one or more polypeptides such as vascular endothelial growth factor (VEGF) receptor-2 (FLK-1), TRK (an NGF receptor), transferrin receptor, and annexin II (lipocortin 2). The cells within (II) express one or more polypeptides such as STRO-1, platelet-derived growth factor (PDGF) receptor, epidermal growth factor (EGF) receptor, CD10 and CD147.

INDEPENDENT CLAIMS are also included for the following:

(1) Distinguishing a population of small and rapidly self-RS cells from a population of large mMSC, by assessing whether at least 29 polypeptides are expressed in the cells in the RS cell population but are not expressed in the mMSC population, and further at least 9 polypeptides are expressed in the population of MSC, but are not expressed in the population of RS cells, where the RS cells are 7 microns in diameter and the cells within the MSC cell population are 15-50 microns in diameter; and

(2) A population of small and rapidly RS cells and mMSC identified by the above method.

ACTIVITY - None given.

MECHANISM OF ACTION - Cell and gene therapy.

No supporting data is given.

USE - The method is useful for distinguishing a population of small and rapidly self-RS cells from a population of large mMSC (claimed). The two classes of bone marrow stem cells, small rapidly self-renewing stem cells and large more mature marrow stromal cells are useful in cell and gene therapy.

Dwg.0/4

ACCESSION NUMBER: 2003-328406 [31] WPIDS

DOC. NO. CPI: C2003-085353

TITLE: Population of cells useful in cell and gene therapy comprise two classes of bone marrow stem cells, small and rapidly self-renewing stem cells, and large more mature

marrow stromal cells .
 DERWENT CLASS: B04 D16
 INVENTOR(S): COLTER, D C; PROCKOP, D J; SEKIYA, I
 PATENT ASSIGNEE(S): (COLT-I) COLTER D C; (PROC-I) PROCKOP D J; (SEKI-I) SEKIYA I
 COUNTRY COUNT: 1
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2002168765	A1	20021114	(200331)*		11

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2002168765	A1	US 2001-816182	20010323

PRIORITY APPLN. INFO: US 2001-816182 20010323

L15 ANSWER 17 OF 17 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
 TI Modulating or assessing **multidrug resistance** related
 to annexin proteins.
 AN 1999-337419 [28] WPIDS
 AB WO 9921980 A UPAB: 19990719
 NOVELTY - Isolated nucleic acid (I) encoding an annexin family member
 (II), i.e. a member of the **MDR (multidrug
 resistance)** gene family, for assessing or modulating **MDR**
 in a cell, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a method for detecting and assessing annexin-based **MDR** by treating test sample with an oligonucleotide (ON) containing 10-50 nucleotides (nt) that hybridize specifically to RNA and/or DNA encoding an annexin, ON being complementary to a sequence of at least 10 consecutive nt from the sequences for annexins I to IX, and detecting any hybrids formed;

(2) kits for this method;

(3) recombinant vector for modulating, **inhibiting** and/or increasing annexin-based **MDR** in a cell, containing (I) linked to a promoter;

(4) cells containing this vector;

(5) a method for identifying compounds that affect annexin-based **MDR** by incubating with test compound in presence or absence of a drug and assessing any effect of the test compound on resistance to the drug;

(6) a method of reducing annexin-based **MDR** by administering a nucleic acid, (dominant negative) mutant of annexin, antibody to annexin, peptide or small molecule;

(7) pharmaceutical composition for reducing **MDR** comprising annexin-based **MDR**-affecting compound and a carrier; and

(8) methods for diagnosing presence of, or predisposition to, annexin-based **MDR** in a patient or pathogen.

ACTIVITY - Antitumor; antifungal.

MECHANISM OF ACTION - None given.

USE - Antisense sequences from (I), or any other agent that **inhibits** (II), are used to prevent **MDR** in animals, particularly in conjunction with cancer treatment. Detecting levels of (II), or related RNA, is used to detect cancer (or pathogens) with **MDR**, or susceptibility. (II) can also be used as a target for identifying therapeutic agents, e.g. antifungal agents, and increasing (II) expression in plants may be used to develop specific resistance.

ACCESSION NUMBER: 1999-337419 [28] WPIDS
 DOC. NO. NON-CPI: N1999-252873
 DOC. NO. CPI: C1999-099183
 TITLE: Modulating or assessing **multidrug resistance** related to annexin proteins.
 DERWENT CLASS: B04 D16 S03
 INVENTOR(S): GEORGES, E; WANG, Y
 PATENT ASSIGNEE(S): (UYMC-N) UNIV MCGILL; (GEOR-I) GEORGES E; (WANG-I) WANG Y
 COUNTRY COUNT: 83
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9921980	A1	19990506	(199928)*	EN	62
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL					
OA PT SD SE SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE					
GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG					
MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG					
US UZ VN YU ZW					
AU 9896174	A	19990517	(199939)		
CA 2219299	A1	19990424	(199940)	EN	
EP 1025225	A1	20000809	(200039)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9921980	A1	WO 1998-CA992	19981026
AU 9896174	A	AU 1998-96174	19981026
CA 2219299	A1	CA 1997-2219299	19971024
EP 1025225	A1	EP 1998-949842	19981026
		WO 1998-CA992	19981026

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9896174	A Based on	WO 9921980
EP 1025225	A1 Based on	WO 9921980

PRIORITY APPLN. INFO: CA 1997-2219299 19971024

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	"Ask CAS" for self-help around the clock
NEWS	3	May 12 EXTEND option available in structure searching
NEWS	4	May 12 Polymer links for the POLYLINK command completed in REGISTRY
NEWS	5	May 27 New UPM (Update Code Maximum) field for more efficient patent SDIs in CAplus
NEWS	6	May 27 CAplus super roles and document types searchable in REGISTRY
NEWS	7	Jun 28 Additional enzyme-catalyzed reactions added to CASREACT
NEWS	8	Jun 28 ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS	9	Jul 12 BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS	10	Jul 30 BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS	11	AUG 02 IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS	12	AUG 02 CAplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS	13	AUG 02 STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS	14	AUG 02 The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS EXPRESS	JULY 30	CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS INTER		General Internet Information
NEWS LOGIN		Welcome Banner and News Items
NEWS PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:15:14 ON 03 AUG 2004

=> file medline, biosis, wpids, fsta, embase, dgene, jicst, japio, uspatful, hcaplus		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'MEDLINE' ENTERED AT 13:15:44 ON 03 AUG 2004

FILE 'BIOSIS' ENTERED AT 13:15:44 ON 03 AUG 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'WPIDS' ENTERED AT 13:15:44 ON 03 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 13:15:44 ON 03 AUG 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'EMBASE' ENTERED AT 13:15:44 ON 03 AUG 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'DGENE' ENTERED AT 13:15:44 ON 03 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'JICST-EPLUS' ENTERED AT 13:15:44 ON 03 AUG 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'JAPIO' ENTERED AT 13:15:44 ON 03 AUG 2004
COPYRIGHT (C) 2004 Japanese Patent Office (JPO)- JAPIO

FILE 'USPATFULL' ENTERED AT 13:15:44 ON 03 AUG 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'HCAPLUS' ENTERED AT 13:15:44 ON 03 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> s MDR adj decrease
L1 0 MDR ADJ DECREASE

=> s MDR adj inhibit?
L2 0 MDR ADJ INHIBIT?

=> s multidrug resistance and inhibit
L3 3517 MULTIDRUG RESISTANCE AND INHIBIT

=> s l3 and compound
L4 1433 L3 AND COMPOUND

=> s l4 and annexin
L5 78 L4 AND ANNEXIN

=> s l5 and annexin
L6 78 L5 AND ANNEXIN

=> s l6 and annexin I
L7 5 L6 AND ANNEXIN I

=> s (multidrug resistance inhibition) with (annexin I)
MISSING OPERATOR HIBITION) WITH
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s (multidrug resistance inhibition) and (annexin I)
L8 0 (MULTIDRUG RESISTANCE INHIBITION) AND (ANNEXIN I)

=> s (multidrug resistance inhibition) near(annexin I)
MISSING OPERATOR HIBITION) NEAR

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

```
=> s (multidrug resistance inhibition) adj2 (annexin I)
MISSING OPERATOR HIBITION) ADJ2
```

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

```
=> s multidrug resistance inhibition
L9          65 MULTIDRUG RESISTANCE INHIBITION
```

```
=> s l9 and annexin
L10         0 L9 AND ANNEXIN
```

```
=> s l9 and annexin I
L11         0 L9 AND ANNEXIN I
```

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 May 12 EXTEND option available in structure searching
NEWS 4 May 12 Polymer links for the POLYLINK command completed in REGISTRY
NEWS 5 May 27 New UPM (Update Code Maximum) field for more efficient patent
SDIs in Cplus
NEWS 6 May 27 Cplus super roles and document types searchable in REGISTRY
NEWS 7 Jun 28 Additional enzyme-catalyzed reactions added to CASREACT
NEWS 8 Jun 28 ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG,
and WATER from CSA now available on STN(R)
NEWS 9 Jul 12 BEILSTEIN enhanced with new display and select options,
resulting in a closer connection to BABS
NEWS 10 Jul 30 BEILSTEIN on STN workshop to be held August 24 in conjunction
with the 228th ACS National Meeting
NEWS 11 AUG 02 IFIPAT/IFIUDE/IFICDB reloaded with new search and display
fields
NEWS 12 AUG 02 Cplus and CA patent records enhanced with European and Japan
Patent Office Classifications
NEWS 13 AUG 02 STN User Update to be held August 22 in conjunction with the
228th ACS National Meeting
NEWS 14 AUG 02 The Analysis Edition of STN Express with Discover!
(Version 7.01 for Windows) now available

NEWS EXPRESS JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:56:22 ON 03 AUG 2004

=> file medline, biosis, embase, dgene, wpids
COST IN U.S. DOLLARS

SINCE FILE TOTAL
ENTRY SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'MEDLINE' ENTERED AT 14:56:36 ON 03 AUG 2004

FILE 'BIOSIS' ENTERED AT 14:56:36 ON 03 AUG 2004

COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 14:56:36 ON 03 AUG 2004

COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'DGENE' ENTERED AT 14:56:36 ON 03 AUG 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPIDS' ENTERED AT 14:56:36 ON 03 AUG 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

=> s lipocortin I

L1 549 LIPOCORTIN I

=> s annexin with MDR

L2 1 ANNEXIN WITH MDR

=> s l1 and MDR

L3 1 L1 AND MDR

=> d l2 ti abs ibib tot

L2 ANSWER 1 OF 1 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN

TI Modulating or assessing multidrug resistance related to annexin proteins.

AN 1999-337419 [28] WPIDS

AB WO 9921980 A UPAB: 19990719

NOVELTY - Isolated nucleic acid (I) encoding an annexin family member (II), i.e. a member of the MDR (multidrug resistance) gene family, for assessing or modulating MDR in a cell, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a method for detecting and assessing **annexin**-based **MDR** by treating test sample with an oligonucleotide (ON) containing 10-50 nucleotides (nt) that hybridize specifically to RNA and/or DNA encoding an annexin, ON being complementary to a sequence of at least 10 consecutive nt from the sequences for annexins I to IX, and detecting any hybrids formed;

(2) kits for this method;

(3) recombinant vector for modulating, inhibiting and/or increasing **annexin**-based **MDR** in a cell, containing (I) linked to a promoter;

(4) cells containing this vector;

(5) a method for identifying compounds that affect **annexin**-based **MDR** by incubating with test compound in presence or absence of a drug and assessing any effect of the test compound on resistance to the drug;

(6) a method of reducing **annexin**-based **MDR** by administering a nucleic acid, (dominant negative) mutant of annexin, antibody to annexin, peptide or small molecule;

(7) pharmaceutical composition for reducing MDR comprising **annexin**-based **MDR**-affecting compound and a carrier; and

(8) methods for diagnosing presence of, or predisposition to, **annexin**-based **MDR** in a patient or pathogen.

ACTIVITY - Antitumor; antifungal.

MECHANISM OF ACTION - None given.

USE - Antisense sequences from (I), or any other agent that inhibits (II), are used to prevent MDR in animals, particularly in conjunction with cancer treatment. Detecting levels of (II), or related RNA, is used to detect cancer (or pathogens) with MDR, or susceptibility. (II) can also be

used as a target for identifying therapeutic agents, e.g. antifungal agents, and increasing (II) expression in plants may be used to develop specific resistance.

Dwg.0/9

ACCESSION NUMBER: 1999-337419 [28] WPIDS
DOC. NO. NON-CPI: N1999-252873
DOC. NO. CPI: C1999-099183
TITLE: Modulating or assessing multidrug resistance related to annexin proteins.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): GEORGES, E; WANG, Y
PATENT ASSIGNEE(S): (UYMC-N) UNIV MCGILL; (GEOR-I) GEORGES E; (WANG-I) WANG Y
COUNTRY COUNT: 83
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9921980	A1	19990506	(199928)*	EN	62
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW					
AU 9896174	A	19990517	(199939)		
CA 2219299	A1	19990424	(199940)	EN	
EP 1025225	A1	20000809	(200039)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9921980	A1	WO 1998-CA992	19981026
AU 9896174	A	AU 1998-96174	19981026
CA 2219299	A1	CA 1997-2219299	19971024
EP 1025225	A1	EP 1998-949842	19981026
		WO 1998-CA992	19981026

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9896174	A Based on	WO 9921980
EP 1025225	A1 Based on	WO 9921980

PRIORITY APPLN. INFO: CA 1997-2219299 19971024

=> d l3 ti abs ibib tot

L3 ANSWER 1 OF 1 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
TI INCREASED TYROSINE PHOSPHORYLATION OF **LIPOCORTIN I** IN
MULTIDRUG RESISTANT SARCOMA 180 CELLS.

ACCESSION NUMBER: 1991:379014 BIOSIS
DOCUMENT NUMBER: PREV199141051404; BR41:51404
TITLE: INCREASED TYROSINE PHOSPHORYLATION OF **LIPOCORTIN I** IN MULTIDRUG RESISTANT SARCOMA 180 CELLS.
AUTHOR(S): BHUSHAN A [Reprint author]; TRITTON T R
CORPORATE SOURCE: DEP PHARMACOL AND VT REGIONAL CANCER CENT, UNIV VT, BURLINGTON, VT 05405, USA
SOURCE: Proceedings of the American Association for Cancer Research Annual Meeting, (1991) Vol. 32, pp. 362.
Meeting Info.: PROCEEDINGS OF THE 82ND ANNUAL MEETING OF

THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, HOUSTON,
TEXAS, USA, MAY 15-18, 1991. PROC AM ASSOC CANCER RES ANNU
MEET.

ISSN: 0197-016X.

DOCUMENT TYPE:

Conference; (Meeting)

FILE SEGMENT:

BR

LANGUAGE:

ENGLISH

ENTRY DATE:

Entered STN: 17 Aug 1991

Last Updated on STN: 17 Aug 1991

Refine Search

Search Results -

Terms	Documents
annexin 1 and L11	671

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L12

Search History

DATE: Tuesday, August 03, 2004 [Printable Copy](#) [Create Case](#)

Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT; PLUR=YES; OP=OR

<u>L12</u>	annexin 1 and L11	671	<u>L12</u>
<u>L11</u>	sacroma cells and L10	159	<u>L11</u>
<u>L10</u>	lipocortin and L9	132	<u>L10</u>
<u>L9</u>	tyrosine phosphorylation	35781	<u>L9</u>
<u>L8</u>	Annexin I and I7	90967	<u>L8</u>
<u>L7</u>	L6 and MDR inhibition	107982	<u>L7</u>
<u>L6</u>	lipocrotin I	1167818	<u>L6</u>
<u>L5</u>	L4 and annexin	7	<u>L5</u>
<u>L4</u>	I2 and MDR	16	<u>L4</u>
<u>L3</u>	Tritton.in.	13	<u>L3</u>
<u>L2</u>	cole.in.	4788	<u>L2</u>
<u>L1</u>	bhushan.in	0	<u>L1</u>

END OF SEARCH HISTORY

Hit List

[Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#)
[Generate OACS](#)

Search Results - Record(s) 1 through 7 of 7 returned.

☐ 1. Document ID: US 6063621 A

L5: Entry 1 of 7

File: USPT

May 16, 2000

US-PAT-NO: 6063621

DOCUMENT-IDENTIFIER: US 6063621 A

**** See image for Certificate of Correction ****

TITLE: Antibodies to a multidrug resistance protein

DATE-ISSUED: May 16, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Deeley; Roger G.	Kingston			CA
<u>Cole</u> ; Susan P. C.	Kingston			CA

US-CL-CURRENT: 435/330; 424/155.1, 530/388.8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequence	Attachment	Claims	KWIC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	--------------------------	----------------------------	--------	------	----------

☐ 2. Document ID: US 6025473 A

L5: Entry 2 of 7

File: USPT

Feb 15, 2000

US-PAT-NO: 6025473

DOCUMENT-IDENTIFIER: US 6025473 A

**** See image for Certificate of Correction ****

TITLE: Multidrug resistance proteins

DATE-ISSUED: February 15, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Deeley; Roger G.	Kingston			CA
<u>Cole</u> ; Susan P. C.	Kingston			CA

US-CL-CURRENT: 530/350; 435/183, 530/300, 530/395, 536/23.5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequence	Attachment	Claims	KWIC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	--------------------------	----------------------------	--------	------	----------

☐ 3. Document ID: US 6001563 A

L5: Entry 3 of 7

File: USPT

Dec 14, 1999

US-PAT-NO: 6001563

DOCUMENT-IDENTIFIER: US 6001563 A

**** See image for Certificate of Correction ****

TITLE: Methods for identifying chemosensitizers

DATE-ISSUED: December 14, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Deeley; Roger G.	Kingston			CA
<u>Cole</u> ; Susan P.C.	Kingston			CA

US-CL-CURRENT: 435/6; 424/9.1, 435/29, 435/325, 435/4, 800/13

Full	Title	Citation	Front	Review	Classification	Date	Reference	Examination	Amendment	Claims	RMIC	Draw Dg
------	-------	----------	-------	--------	----------------	------	-----------	-------------	-----------	--------	------	---------

☐ 4. Document ID: US 5891724 A

L5: Entry 4 of 7

File: USPT

Apr 6, 1999

US-PAT-NO: 5891724

DOCUMENT-IDENTIFIER: US 5891724 A

**** See image for Certificate of Correction ****

TITLE: Methods for conferring multidrug resistance on a cell

DATE-ISSUED: April 6, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Deeley; Roger G.	Kingston			CA
<u>Cole</u> ; Susan P. C.	Kingston			CA

US-CL-CURRENT: 435/375; 435/320.1, 435/325, 435/367, 435/456, 435/6, 435/69.1,
536/23.1, 536/23.5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Examination	Amendment	Claims	RMIC	Draw Dg
------	-------	----------	-------	--------	----------------	------	-----------	-------------	-----------	--------	------	---------

☐ 5. Document ID: US 5882875 A

L5: Entry 5 of 7

File: USPT

Mar 16, 1999

US-PAT-NO: 5882875

DOCUMENT-IDENTIFIER: US 5882875 A

**** See image for Certificate of Correction ****

TITLE: Methods for identifying multidrug resistant tumor cells

DATE-ISSUED: March 16, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Deeley; Roger G.	Kingston			CA
<u>Cole</u> ; Susan P. C.	Kingston			CA

US-CL-CURRENT: 435/7.23; 424/155.1, 530/388.8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMHC	Draw De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	---------

☐ 6. Document ID: US 5766880 A

L5: Entry 6 of 7

File: USPT

Jun 16, 1998

US-PAT-NO: 5766880

DOCUMENT-IDENTIFIER: US 5766880 A

TITLE: Isolated nucleic acid molecules encoding multidrug resistance proteins

DATE-ISSUED: June 16, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Deeley; Roger G.	Kingston			CA
<u>Cole</u> ; Susan P.C.	Kingston			CA

US-CL-CURRENT: 435/69.1; 435/243, 435/320.1, 435/366, 435/372, 536/23.5, 536/24.31

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMHC	Draw De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	---------

☐ 7. Document ID: US 5489519 A

L5: Entry 7 of 7

File: USPT

Feb 6, 1996

US-PAT-NO: 5489519

DOCUMENT-IDENTIFIER: US 5489519 A

**** See image for Certificate of Correction ****

TITLE: Multidrug resistance protein

DATE-ISSUED: February 6, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Deeley; Roger G.	Kingston			CA
<u>Cole</u> ; Susan P. C.	Kingston			CA

US-CL-CURRENT: [435/69.1](#); [435/320.1](#), [435/372](#), [435/69.7](#), [536/23.5](#), [536/24.5](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequence	Attachments	Claims	AMC	Draw De
------	-------	----------	-------	--------	----------------	------	-----------	----------	-------------	--------	-----	---------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
L4 and annexin	7

Display Format: [Previous Page](#) [Next Page](#) [Go to Doc#](#)

Refine Search

Search Results -

Terms	Documents
L23 and L26	122

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L27

Search History

DATE: Tuesday, August 03, 2004 [Printable Copy](#) [Create Case](#)

Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT; PLUR=YES; OP=OR

<u>L27</u>	l23 and L26	122	<u>L27</u>
<u>L26</u>	george.in.	145012	<u>L26</u>
<u>L25</u>	georges.in.	145012	<u>L25</u>
<u>L24</u>	L23 and georges	764	<u>L24</u>
<u>L23</u>	wang.in.	12989	<u>L23</u>
<u>L22</u>	L21 and annexin	463	<u>L22</u>
<u>L21</u>	l20 and dominant negative mutant	498124	<u>L21</u>
<u>L20</u>	l17 and antibody	763	<u>L20</u>
<u>L19</u>	MDR adj2 annexin I	1167818	<u>L19</u>
<u>L18</u>	MDR adj1 inhibit	0	<u>L18</u>
<u>L17</u>	L16 and l14	1168	<u>L17</u>
<u>L16</u>	multidrug resistance with inhibit	5051	<u>L16</u>
<u>L15</u>	l7 and L14	372	<u>L15</u>
<u>L14</u>	annexin I and L13	1670	<u>L14</u>

<u>L13</u>	inhibition and L12	1206	<u>L13</u>
<u>L12</u>	multidrug resistance with annexin	1661	<u>L12</u>
<u>L11</u>	l9 and L10	77766	<u>L11</u>
<u>L10</u>	(annexin based multidrug resistance)	1583919	<u>L10</u>
<u>L9</u>	Annexin inhibition	107228	<u>L9</u>
<u>L8</u>	l1 and L7	1	<u>L8</u>
<u>L7</u>	L6 and l5	372	<u>L7</u>
<u>L6</u>	l2 and annexin	373	<u>L6</u>
<u>L5</u>	L4 and annexin I	1167822	<u>L5</u>
<u>L4</u>	l2 and inhibit	72589	<u>L4</u>
<u>L3</u>	l1 and L2	1	<u>L3</u>
<u>L2</u>	multidrug resistance	750917	<u>L2</u>
<u>L1</u>	6362321.pn.	1	<u>L1</u>

END OF SEARCH HISTORY